Journal article

Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia Beyond Ibrutinib

Masa Lasica, Constantine S Tam

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | W B SAUNDERS CO-ELSEVIER INC | Published : 2021

Abstract

Bruton tyrosine kinase inhibitors have indisputably transformed the treatment landscape of chronic lymphocytic leukemia, but require continuous therapy to maintain response. This places emphasis on their unique toxicity profile and potential loss of efficacy owing to resistance. Data from single-arm clinical studies are suggestive of comparable efficacy and favorable toxicity profiles of next-generation Bruton tyrosine kinase inhibitors. This is supported by the ASPEN study in Waldenstrom's macroglobulinemia, which convincingly demonstrated that zanubrutinib has a better toxicity profile than ibrutinib. Novel, reversible Bruton tyrosine kinase inhibitors are showing the potential to improve ..

View full abstract